Our previous research using flow cytometry technology found significantly reduced CD8+ TN and increased CD8+ TE/M in both NMOSD and MS, while decreased CD8+ TMP was only observed in NMOSD. The gene discussed is CD8A; the disease is myeloid sarcoma.